<DOC>
	<DOCNO>NCT00090220</DOCNO>
	<brief_summary>This study conduct assess safety , immunogenicity , efficacy long-term effectiveness vaccine evaluate prevention human papillomavirus ( HPV ) infection disease mid-adult woman .</brief_summary>
	<brief_title>A Study Evaluate Safety , Immune Response , Efficacy Gardasil ( V501 , qHPV ) Mid-Adult Women ( V501-019 )</brief_title>
	<detailed_description>The Base study vaccination period ( V501-019 ) encompass Day 1 Month 7 , time participant receive randomly assign , blind Gardasilâ„¢ ( V501 , qHPV vaccine ) placebo Day 1 , Month 2 Month 6 . The Base study follow-up period continue approximately Month 48 . The base study extend protocol V501-019-10 ( EXT1 ) . Participants receive placebo participant receive 1 dose qHPV vaccine Base Study offer complete , open-label , 3-dose qHPV vaccine regimen ( administered EXT1 Day 1 , Month 2 Month 6 ) . Participants receive 2 dos qHPV vaccine base study offer single additional dose qHPV vaccine ( administered EXT1 Day 1 ) . Participants follow EXT1 Month 7 . A Long Term Follow-Up ( LTFU ) extension study V501-019-21 ( EXT2 ) add observe long term safety , effectiveness , immunogenicity qHPV vaccine approximately 1,600 woman participate Base Study sit Colombia . Data collect period 6-10 year follow participant 's enrollment original Base Study .</detailed_description>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>No history genital wart , vulvar intraepithelial neoplasia ( VIN ) , vaginal intraepithelial neoplasia ( VaIN ) Not pregnant agrees use effective contraception Month 7 study Additional criterion apply Pregnant Concurrently enrol clinical study involve collection cervical specimens Previously receive HPV vaccine History severe allergic reaction require medical intervention Received immune globulin bloodderived product within 3 month prior first study injection History splenectomy , know immune disorder , receive immunosuppressive Immunocompromised diagnosed human immunodeficiency virus ( HIV ) infection Known thrombocytopenia coagulation disorder could contraindicate intramuscular injection History recent ongoing alcohol drug abuse Prior treatment genital wart , VIN , VaIN History cervical disease ( ie , surgical treatment cervical lesion ) Hysterectomy</criteria>
	<gender>Female</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>